The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Who should have statins 18 th March Nonfatal MI CHD death Any major coronary event CABG PTCA Unspecified Any coronary revascularisation.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta- analysis of the randomised trials The Lancet Volume 386, Issue 10001,

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Volume 376, Issue 9753, Pages (November 2010)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Volume 385, Issue 9985, Pages (June 2015)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

2013 ACC/AHA cholesterol treatment guidelines

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Volume 376, Issue 9734, Pages (July 2010)

Volume 388, Issue 10059, Pages (November 2016)

Long-term effects of hormone replacement therapy

Volume 378, Issue 9804, Pages (November 2011)

Meta-analysis of randomised controlled trials

Volume 388, Issue 10059, Pages (November 2016)

Baseline characteristics of HPS participants by prior diabetes

Volume 376, Issue 9734, Pages (July 2010)

The results of the SHARP trial

Long-term effects of hormone replacement therapy

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Aspirin in the prevention of cancer – Author's reply

Drug therapy for coronary heart disease: the Sheffield table

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

Age-specific relevance of usual blood pressure to vascular mortality

Statins for prevention of stroke

Mortality risk with dual antiplatelet therapy?

Volume 9, Issue 9, Pages (September 2010)

Volume 386, Issue 10001, Pages (October 2015)

Volume 381, Issue 9875, Pages (April 2013)

Volume 379, Issue 9822, Pages (March 2012)

2013 ACC/AHA cholesterol treatment guidelines

Adrian Martineau The Lancet Respiratory Medicine

Volume 375, Issue 9725, Pages (May 2010)

MRC/BHF Heart Protection Study

Potential mechanisms whereby statins may reduce the risk of stroke

Volume 385, Issue 9985, Pages (June 2015)

Volume 375, Issue 9709, Pages (January 2010)

Infant-feeding patterns and HIV-1 transmission

Volume 376, Issue 9753, Pages (November 2010)

Volume 371, Issue 9627, Pages (May 2008)

Volume 378, Issue 9786, Pages (July 2011)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Volume 382, Issue 9894, Pages (August 2013)

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient.

Volume 379, Issue 9822, Pages (March 2012)

Cause of death Treatment-arm events, % (n=45 054)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

The results of the SHARP trial

Presentation transcript:

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Cholesterol Treatment Trialists' (CTT) Collaborators The Lancet Volume 380, Issue 9841, Pages 581-590 (August 2012) DOI: 10.1016/S0140-6736(12)60367-5 Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 1 Effects on major coronary events, strokes, coronary revascularisation procedures, and major vascular events per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk MVE=major vascular event. RR=rate ratio. CI=confidence interval. The Lancet 2012 380, 581-590DOI: (10.1016/S0140-6736(12)60367-5) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 2 Effects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk, by history of vascular disease MVE=major vascular event. RR=rate ratio. CI=confidence interval. The Lancet 2012 380, 581-590DOI: (10.1016/S0140-6736(12)60367-5) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 3 Effects on vascular and non-vascular deaths per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk, by history of vascular disease MVE=major vascular event. RR=rate ratio. CI=confidence interval. There were a further 179 (statin/more statin) versus 210 (control/less statin) deaths of unknown cause among participants without vascular disease and 309 (statin/more statin) versus 338 (control/less statin) deaths of unknown cause among participants with vascular disease. The Lancet 2012 380, 581-590DOI: (10.1016/S0140-6736(12)60367-5) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 4 Effects on cancer incidence and cancer mortality per 1·0 mmol/L reduction in LDL cholesterol at different levels of risk MVE=major vascular event. RR=rate ratio. CI=confidence interval. The Lancet 2012 380, 581-590DOI: (10.1016/S0140-6736(12)60367-5) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 5 Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk (A) Major vascular events and (B) vascular deaths. Lifetable estimates using major vascular event risk or vascular death risk in the respective risk categories and overall treatment effects per 1·0 mmol/L reduction in LDL cholesterol with statin. The Lancet 2012 380, 581-590DOI: (10.1016/S0140-6736(12)60367-5) Copyright © 2012 Elsevier Ltd Terms and Conditions